A needle and the damage done: Fatal forty DDI: Buprenorphine, ritonavir, CYP3A4

James Hilliard, Kirk Lalwani

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

This case discusses a pharmacokinetic drug interaction between buprenorphine, ritonavir, and atazanavir. Buprenorphine is a cytochrome P450 3A4 substrate. Ritonavir and atazanavir are both potent 3A4 inhibitors.

Original languageEnglish (US)
Title of host publicationA Case Approach to Perioperative Drug-Drug Interactions
PublisherSpringer New York
Pages245-247
Number of pages3
ISBN (Print)9781461474951, 9781461474944
DOIs
StatePublished - Sep 15 2015

Fingerprint

Cytochrome P-450 CYP3A
Ritonavir
Buprenorphine
Needles
Drug Interactions
Pharmacokinetics
Atazanavir Sulfate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hilliard, J., & Lalwani, K. (2015). A needle and the damage done: Fatal forty DDI: Buprenorphine, ritonavir, CYP3A4. In A Case Approach to Perioperative Drug-Drug Interactions (pp. 245-247). Springer New York. https://doi.org/10.1007/978-1-4614-7495-1_50

A needle and the damage done : Fatal forty DDI: Buprenorphine, ritonavir, CYP3A4. / Hilliard, James; Lalwani, Kirk.

A Case Approach to Perioperative Drug-Drug Interactions. Springer New York, 2015. p. 245-247.

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Hilliard, J & Lalwani, K 2015, A needle and the damage done: Fatal forty DDI: Buprenorphine, ritonavir, CYP3A4. in A Case Approach to Perioperative Drug-Drug Interactions. Springer New York, pp. 245-247. https://doi.org/10.1007/978-1-4614-7495-1_50
Hilliard J, Lalwani K. A needle and the damage done: Fatal forty DDI: Buprenorphine, ritonavir, CYP3A4. In A Case Approach to Perioperative Drug-Drug Interactions. Springer New York. 2015. p. 245-247 https://doi.org/10.1007/978-1-4614-7495-1_50
Hilliard, James ; Lalwani, Kirk. / A needle and the damage done : Fatal forty DDI: Buprenorphine, ritonavir, CYP3A4. A Case Approach to Perioperative Drug-Drug Interactions. Springer New York, 2015. pp. 245-247
@inbook{90c988ae363443c1893d247bbc2a0090,
title = "A needle and the damage done: Fatal forty DDI: Buprenorphine, ritonavir, CYP3A4",
abstract = "This case discusses a pharmacokinetic drug interaction between buprenorphine, ritonavir, and atazanavir. Buprenorphine is a cytochrome P450 3A4 substrate. Ritonavir and atazanavir are both potent 3A4 inhibitors.",
author = "James Hilliard and Kirk Lalwani",
year = "2015",
month = "9",
day = "15",
doi = "10.1007/978-1-4614-7495-1_50",
language = "English (US)",
isbn = "9781461474951",
pages = "245--247",
booktitle = "A Case Approach to Perioperative Drug-Drug Interactions",
publisher = "Springer New York",

}

TY - CHAP

T1 - A needle and the damage done

T2 - Fatal forty DDI: Buprenorphine, ritonavir, CYP3A4

AU - Hilliard, James

AU - Lalwani, Kirk

PY - 2015/9/15

Y1 - 2015/9/15

N2 - This case discusses a pharmacokinetic drug interaction between buprenorphine, ritonavir, and atazanavir. Buprenorphine is a cytochrome P450 3A4 substrate. Ritonavir and atazanavir are both potent 3A4 inhibitors.

AB - This case discusses a pharmacokinetic drug interaction between buprenorphine, ritonavir, and atazanavir. Buprenorphine is a cytochrome P450 3A4 substrate. Ritonavir and atazanavir are both potent 3A4 inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=84955355015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955355015&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-7495-1_50

DO - 10.1007/978-1-4614-7495-1_50

M3 - Chapter

AN - SCOPUS:84955355015

SN - 9781461474951

SN - 9781461474944

SP - 245

EP - 247

BT - A Case Approach to Perioperative Drug-Drug Interactions

PB - Springer New York

ER -

Access to Document